NCT01491607Phase 3Completed

Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults

Study sponsor: Emergent BioSolutions

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2012-05Actual
Enrollment · participants200Actual
Source updated2024-04-09Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.